Protocol Ledger

NCT03780543 · Phase II · TERMINATED

A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

Interventional Phase II clinical trial protocol NCT03780543 sponsored by Assembly Biosciences in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-20 Enrollment: 92 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03780543
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)92 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03780543
Protocol FieldVerified Registry Value
NCT IdentifierNCT03780543
Consolidated Lead SponsorAssembly Biosciences
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment92 participants (ACTUAL)
Registered Start Date2018-12-20
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI